AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Target
Upside 478%
Price (€) 1.95
Market Cap (€M) 71.2
Perf. 1W: -7.05%
Perf. 1M: -5.04%
Perf. 3M: -51.1%
Perf Ytd: -60.4%
10 day relative perf. to stoxx600: -15.1%
20 day relative perf. to stoxx600: -8.06%
EPS change18/08/2021

Change in EPS2021 : € 0.18 vs 0.18-0.32%
2022 : € 0.91 vs 0.91-0.32%

We have only integrated the detailed numbers for FY20, which translate into a slightly lower EPS. However, the change is not meaningful given the still very low level of results of the company before its products reach the market.



Updates

31 Mar 21 Earnings/sales releases
FY20 unsuprising; waiting for more

15 Dec 20 Financing issue
A double bond issue

21 Sep 20 Earnings/sales releases
Update on the group's business

29 Mar 20 Earnings/sales releases
Meaningless FY19 results and product update

23 Dec 19 Financing issue
Extra-financing to increase visibility

20 Nov 19 Financing issue
A €2.6m non-dilutive issue

.